Roche Holding Feed

	Est. tid*
2027-01-28	N/A	Bokslutskommuniké 2026
2026-07-23	N/A	Kvartalsrapport 2026-Q2
2026-03-12	-	X-dag bonusutdelning RO 0.999
2026-03-12	-	X-dag ordinarie utdelning ROG 9.80 CHF
2026-03-12	-	X-dag ordinarie utdelning RO 9.80 CHF
2026-03-10	-	Årsstämma
2026-01-29	-	Bokslutskommuniké 2025
2025-07-24	-	Kvartalsrapport 2025-Q2
2025-03-27	-	X-dag ordinarie utdelning ROG 9.70 CHF
2025-03-27	-	X-dag ordinarie utdelning RO 9.70 CHF
2025-03-25	-	Årsstämma
2025-01-30	-	Bokslutskommuniké 2024
2024-03-14	-	X-dag ordinarie utdelning RO 9.60 CHF
2024-03-14	-	X-dag ordinarie utdelning ROG 9.60 CHF
2024-03-12	-	Årsstämma
2023-03-16	-	X-dag ordinarie utdelning RO 9.50 CHF
2023-03-16	-	X-dag ordinarie utdelning ROG 9.50 CHF
2022-03-17	-	X-dag ordinarie utdelning ROG 9.30 CHF
2022-03-17	-	X-dag ordinarie utdelning RO 9.30 CHF
2022-03-15	-	Årsstämma
2021-11-26	-	Extra Bolagsstämma
2021-03-18	-	X-dag ordinarie utdelning RO 9.10 CHF
2021-03-18	-	X-dag ordinarie utdelning ROG 9.10 CHF
2021-03-16	-	Årsstämma
2020-03-19	-	X-dag ordinarie utdelning ROG 9.00 CHF
2020-03-19	-	X-dag ordinarie utdelning RO 9.00 CHF
2020-03-17	-	Årsstämma

Land	Schweiz
Sektor	Hälsovård
Industri	Läkemedel & Handel

2026-04-13 07:00:00 Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

2026-03-30 07:00:00 Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

2026-03-23 16:00:00 Roche eröffnet neues Forschungsgebäude für das Institute of Human Biology und leistet damit Pionierarbeit im Bereich menschlicher Modellsysteme, um Entwicklung von Medikamenten zu beschleunigen

2026-03-23 16:00:00 Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development

2026-03-16 21:30:00 Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

2026-03-10 14:15:00 Roche Generalversammlung 2026 334,45 CHF | +1,13%

2026-03-10 14:15:00 Assemblée générale annuelle 2026 de Roche 334,45 CHF | +1,13%

2026-03-10 14:15:00 Roche Annual General Meeting 2026 334,45 CHF | +1,13%

2026-03-09 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer 330,70 CHF | -3,11%

2026-03-06 14:45:00 New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus 341,30 CHF | -2,93%

2026-03-05 19:45:00 Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity 341,30 CHF | -2,93%

2026-03-02 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1) 361,60 CHF | -2,28%

2026-02-20 07:00:00 FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer 366,30 CHF | -0,27%

2026-02-17 07:00:00 Change to the Roche Enlarged Corporate Executive Committee 369,20 CHF | +2,43%

2026-02-16 07:00:00 Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease 360,45 CHF | -0,12%

2026-02-07 21:40:00 Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

2026-01-29 07:00:00 [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7% 347,90 CHF | +2,81%

2026-01-29 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth 347,90 CHF | +2,81%

2026-01-27 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity 351,35 CHF | +0,47%

2025-12-22 07:00:00 FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma 325,15 CHF | -0,41%

2025-12-11 07:00:00 Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu 318,30 CHF | -1,46%

2025-12-10 14:15:00 Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer 323,00 CHF | +2,18%

2025-12-09 07:10:00 Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark 316,10 CHF | -0,66%

2025-12-09 07:00:00 European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis 316,10 CHF | -0,66%

2025-12-08 22:30:00 Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas 316,10 CHF | -0,66%

2025-12-02 07:00:00 Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis) 313,30 CHF | +1,70%

2025-11-19 07:00:00 European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma 310,05 CHF | +1,09%

2025-11-18 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer 306,70 CHF | +7,01%

2025-11-10 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis 279,90 CHF | +4,38%

2025-11-03 15:00:00 Roche to present new data from its broad and innovative haematology portfolio at ASH 2025 259,75 CHF | +0,44%

2025-11-03 07:00:00 Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus 259,75 CHF | +0,44%

2025-10-30 07:00:00 Roche purchases shares in tender offer for 89bio, Inc 261,20 CHF | +0,35%

2025-10-29 07:00:00 Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue 260,30 CHF | +0,04%

2025-10-28 07:00:00 Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome 260,20 CHF | -2,51%

2025-10-23 07:30:00 Changes to the Roche Enlarged Corporate Executive Committee 271,75 CHF | -2,91%

2025-10-23 07:00:00 [Ad-hoc-Mitteilung gemäss Art. 53] Roche setzt starkes Wachstum in den ersten neun Monaten 2025 fort: Verkäufe steigen um 7% (CER) – Gewinnprognose für das Gesamtjahr erhöht 271,75 CHF | -2,91%

2025-10-23 07:00:00 [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised 271,75 CHF | -2,91%

2025-10-20 07:05:00 Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment 281,05 CHF | -1,07%

2025-10-20 07:00:00 FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis 281,05 CHF | -1,07%

2025-10-18 07:00:00 Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer

2025-10-17 22:20:00 Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

2025-10-17 12:30:00 CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis 284,10 CHF | -0,16%

2025-10-16 07:00:00 Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025 284,55 CHF | +0,71%

2025-10-13 07:00:00 Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types 290,20 CHF | -0,19%

2025-10-06 07:00:00 Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel 288,40 CHF | +0,54%

2025-10-03 07:05:00 FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer 286,85 CHF | +0,90%

2025-10-03 07:00:00 Change in the Roche Board of Directors 286,85 CHF | +0,90%

2025-10-01 22:30:00 Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash 284,30 CHF | +0,98%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Roche Holding

Kalender

Beskrivning

Vem äger bolaget?

Roche Holding

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden